Inhalable asthma treatment does not reduce number of days it takes to clear COVID-19 symptoms - but does lower risk of hospital visits linked to the virus

Daily Mail and Med Page Today reported on UB research suggesting that ciclesonide, an inhalable asthma treatment, did not help lessen the number of days COVID-19 patients experience symptoms. However, the team did find that the treatment group, when compared to the control group, was less likely to visit the emergency room or become hospitalized for reasons related to COVID-19. “Any COVID-19 treatment that can reduce emergency room visits or hospital admissions provides a benefit not just to the patient, but also the health care system and the community at large,” said Brian Clemency, professor of emergency medicine in the Jacobs School and the study’s first author. What’s New 2-Day, Press From, and Niagara Frontier Publications also provided coverage.